BREAKING NEWS
WILLOUGHBY, Ohio [October 29, 2026] — Dr. Seeds and Medivive announce the launch of the Redox Smart Pen, an innovative pre-filled autoinjector peptide delivery system designed to improve precision and consistency in physician-directed peptide protocols.
Importantly, the Redox Smart Pen was developed through a proprietary methodology focused on uniform potency, accuracy of administration, and high-quality peptides. This technology gives physicians confidence in the formulations they prescribe, while improving the patient experience.
The announcement comes as the U.S. Department of Health and Human Services (HHS) outlines an interim policy that could expand access to six compounded peptides, including BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, through licensed 503A compounding pharmacies under specified regulatory conditions.
As the regulatory landscape surrounding peptide therapy continues to evolve, SSRP remains focused on advancing the clinical application of cellular medicine through expert professional education, physician oversight, and pharmaceutical quality.
Addressing a Critical Component of Peptide Therapy
Developed in collaboration with Medivive, the Redox Smart Pen addresses a critical consideration in peptide administration: the ability to consistently deliver high-quality peptides in the intended dose.
Traditional peptide administration can require patients to reconstitute medication, measure individual doses, and prepare injections themselves. These additional steps often introduce unintended variability, potentially affecting dosing accuracy, quality, patient adherence, and a physician’s ability to evaluate protocol effectiveness. All before even considering the legality and validity of sourcing.
The Redox Smart Pen is designed to simplify this process by providing a pre-filled delivery system that reduces the need for manual preparation and measurement and supports physician-directed protocols, without replacing individualized clinical decision-making. Crucially, it is fulfilled direct-to-patient from a licensed 503A compounding pharmacy.
Initial Focus on BPC-157, TB-500, and Semax
The initial introduction of the Redox Smart Pen will focus on three peptides: BPC-157, TB-500, and Semax. SSRP emphasizes that the clinical application of peptide therapies requires an understanding of the underlying molecular pathways, available scientific evidence, patient-specific considerations, and applicable regulatory requirements.
The Redox Smart Pen represents a new pedigree of peptide therapy through a standardized, reproducible manufacturing methodology and a delivery system for consistent products. The Redox Smart Pen is expected to become available to participating providers in November 2026.
To learn more, visit redoxpen.com.
Compounded medications are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing.
